Patel K R, Tin G W, Williams L E, Baldeschwieler J D
J Nucl Med. 1985 Sep;26(9):1048-55.
Murine biodistributions of vesicle-encapsulated [111In]NTA were obtained under a number of conditions. These included normal animals, those bearing s.c.- or i.v.-implanted Lewis Lung Carcinoma (LLC) and those having both s.c.-LLC and sterile granuloma. Variations in the distributions were observed with a preinjection of unlabeled aminomannose (AM) vesicles or an increase in the labeled vesicle size. It was found that s.c. LLC exhibited uptake of between 10 and 25% injected dose/g (% ID/g) depending upon tumor mass with larger lesions having lower accumulation. Significant uptake enhancement (p less than 0.05) occurred after AM blockade. Similar results hold for the i.v.-injected LLC cells implying targeting to both primary and metastatic sites. By increasing vesicle size by a factor of 4, uptake by s.c. LLC declined to essentially blood levels; e.g., 2% ID/g. Granuloma accumulations were also at circulating values and, unlike s.c. LLC, could not be imaged.
在多种条件下获得了囊泡包裹的[111In]NTA在小鼠体内的生物分布情况。这些条件包括正常动物、皮下或静脉注射植入Lewis肺癌（LLC）的动物以及同时患有皮下LLC和无菌性肉芽肿的动物。在预先注射未标记的氨基甘露糖（AM）囊泡或增加标记囊泡大小时，观察到分布情况有所变化。结果发现，皮下LLC的摄取量为每克注射剂量的10%至25%（%ID/g），具体取决于肿瘤大小，肿瘤越大，积累量越低。AM阻断后摄取显著增强（p小于0.05）。静脉注射LLC细胞也有类似结果，这意味着对原发和转移部位均有靶向作用。将囊泡大小增加4倍后，皮下LLC的摄取量降至基本与血液水平相当；例如，2%ID/g。肉芽肿的积累量也处于循环值水平，与皮下LLC不同，无法成像。
